nach oben

CNS Drugs

Erschienen in:

01.09.2008 | Review Article

Riluzole in the Treatment of Mood and Anxiety Disorders

verfasst von: Dr Christopher Pittenger, Vladimir Coric, Mounira Banasr, Michael Bloch, John H. Krystal, Gerard Sanacora

Erschienen in: CNS Drugs | Ausgabe 9/2008

Einloggen, um Zugang zu erhalten

Abstract

Recent advances implicate amino acid neurotransmission in the pathophysiology and treatment of mood and anxiety disorders. Riluzole, which is approved and marketed for the treatment of amyotrophic lateral sclerosis, is thought to be neuroprotective through its modulation of glutamatergic neurotransmission. Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate.

Although double-blind, placebo-controlled trials are lacking, several open-label trials have suggested that riluzole, either as monotherapy or as augmentation of standard therapy, reduces symptoms of obsessive-compulsive disorder, unipolar and bipolar depression, and generalized anxiety disorder. In studies of psychiatrically ill patients conducted to date, the drug has been quite well tolerated; common adverse effects include nausea and sedation. Elevation of liver function tests is common and necessitates periodic monitoring, but has been without clinical consequence in studies conducted to date in psychiatric populations. Case reports suggest utility in other conditions, including trichotillomania and self-injurious behaviour associated with borderline personality disorder. Riluzole may hold promise for the treatment of several psychiatric conditions, possibly through its ability to modulate pathologically dysregulated glutamate levels, and merits further investigation.

The use of trade names is for product identification purposes only and does not imply endorsement.

Heninger GR, Delgardo PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996; 29: 2–11PubMedCrossRef

Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–17PubMedCrossRef

Berman RM, Krystal JH, Charney DS. Mechanisms of action of antidepressants: monoamine hypotheses and beyond. In: Watson SJ, editor. Biology of schizophrenia and affective disease. Washington, DC: American Psychiatric Press, 1996: 295–368

Krystal JH, Sanacora G, Blumberg H, et al. Glutamate and GABA Systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002; 7: S71–80PubMedCrossRef

Sanacora G, Rothman DL, Mason G, et al. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci 2003; 1003: 292–308PubMedCrossRef

Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 3: 69–81PubMedCrossRef

Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx 2006; 3: 57–68PubMedCrossRef

Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis: ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585–91PubMedCrossRef

Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425–31PubMed

10.

Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Coch-rane Database Syst Rev 2007; (1): CD001447

11.

Zarate Jr CA, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161: 171–4PubMedCrossRef

12.

Sanacora G, Kendell SF, Fenton L, et al. Riluzole augmentation for treatment-resistant depression [letter]. Am J Psychiatry 2004; 161: 2132PubMedCrossRef

13.

Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61: 822–5PubMedCrossRef

14.

Zarate Jr CA, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57: 430–2PubMedCrossRef

15.

Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive compulsive disorder and major depressive disorder. Psychopharm (Berl) 2003; 167: 219–20

16.

Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005; 58: 424–8PubMedCrossRef

17.

Pittenger C, Kelmendi B, Wasylink S, et al. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psycho-pharmacol 2008; 28: 363–7CrossRef

18.

Grant P, Lougee L, Hirschtritt M, et al. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007; 17: 761–7PubMedCrossRef

19.

Mathew SJ, Amiel JM, Coplan JD, et al. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 2005; 162: 2379–81PubMedCrossRef

20.

Benavides J, Camelin JC, Mitrani N, et al. 2-Amino-6-trifluo-romethoxy benzothiazole, a possible antagonist of excitatory neurotransmission: II. Biochemical properties. Neuropharm 1985; 24: 1085–92CrossRef

21.

Mizoule J, Meldrum B, Mazadier M, et al. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission: I. Anticonvulsant properties. Neuropharm 1985; 24: 767–73CrossRef

22.

Barneoud P, Mazadier M, Miquet JM, et al. Neuroprotective effects of riluzole on a model of Parkinson’s disease in the rat. Neurosci 1996; 74: 971–83

23.

Bezard E, Stutzmann JM, Imbert C, et al. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur J Pharmacol 1998; 356: 101–4PubMedCrossRef

24.

Storch A, Burkhardt K, Ludolph AC, et al. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem 2000; 75: 2259–69PubMedCrossRef

25.

Obinu MC, Reibaud M, Blanchard V, et al. Neuroprotective effect of riluzole in a primate model of Parkinson’s disease: behavioral and histological evidence. Mov Disord 2002; 17: 13–9PubMedCrossRef

26.

Schiefer J, Landwehrmeyer GB, Luesse HG, et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington’s disease. Mov Disord 2002; 17: 748–57PubMedCrossRef

27.

Wu J, Tang T, Bezprozvanny I. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington’s disease. Neurosci Lett 2006; 407: 219–23PubMedCrossRef

28.

Gurney ME, Fleck ME, Himes CS, et al. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998; 50: 62–6PubMedCrossRef

29.

Stutzmann JM, Pratt J, Boraud T, et al. The effect of riluzole on post-traumatic spinal cord injury in the rat. Neuroreport 1996; 7: 387–92PubMedCrossRef

30.

Mclntosh TK, Smith DH, Voddi M, et al. Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat. J Neurotrauma 1996; 13: 767–80CrossRef

31.

Bareyre F, Wahl F, Mclntosh TK, et al. Time course of cerebral edema after traumatic brain injury in rats: effects of rliuzole and mannitol. J Neurotrauma 1997; 14: 839–49PubMedCrossRef

32.

Wahl F, Renou E, Stutzmann JM. Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury. Brain Res 1997; 756: 247–53PubMedCrossRef

33.

Zhang C, Raghupathi R, Saatman KE, et al. Riluzole attenuates cortical lesion size, but not hippocampal neuronal loss, following traumatic brain injury in the rat. J Neurosci Res 1998; 52: 342–9PubMedCrossRef

34.

Wahl F, Stutzmann JM. Neuroprotective effects of riluzole in neurotrauma models: a review. Acta Neurochir Suppl 1999; 73: 103–10

35.

Malgouris C, Bardot F, Daniel F, et al. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 1989; 9: 3720–7PubMed

36.

Risterucci C, Coccurello R, Banasr M, et al. The metabotropic glutamate receptor subtype 5 antagonist MPEP and the Na(+) channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficts induced by excitotoxic prefrontal cortex lesios. Neurosci 2006; 137: 211–20CrossRef

37.

Wahl F, Allix M, Plotkine M, et al. Effect of riluzole on focal cerebral ischemia in rats. Eur J Pharmacol 1993; 230: 209–14PubMedCrossRef

38.

Pratt J, Rataud J, Bardot F, et al. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci Lett 1992; 140: 225–30PubMedCrossRef

39.

Mottet I, Demeure R, Rataud J, et al. Effects of riluzole on the evolution of focal cerebral ischemia: a magnetic resonance imaging study. MAGMA 1997; 5: 185–91PubMedCrossRef

40.

Heurteaux C, Laigle C, Blondeau N, et al. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 2006; 137: 241–51PubMedCrossRef

41.

Snyder SH, Ferris CD. Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 2000; 157: 1738–51PubMedCrossRef

42.

Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65:1–105PubMedCrossRef

43.

Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61: 705–13PubMedCrossRef

44.

Shepherd GM, editor. The synaptic organization of the brain. 5th ed. New York: Oxford University Press, 2003

45.

Hubert JP, Doble A. Ibotenic acid stimulates D-3H-aspartate release from cultured cerebellar granule cells. Neurosci Lett 1989; 96: 345–50PubMedCrossRef

46.

Chéramy A, Barbeito L, Godeheu G, et al. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992; 147: 209–12PubMedCrossRef

47.

Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA 1. Eur J Pharmacol 1993; 250: 473–6PubMedCrossRef

48.

Jehle T, Bauer J, Blauth E, et al. Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol 2000; 130: 1227–34PubMedCrossRef

49.

Prakriya M, Menerick S. Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron 2000; 26: 671–82PubMedCrossRef

50.

Benoit E, Escande D. Rliuzole specifically blocks inactivated Na chanels in myelinated nerve fibres. Pflügers Arch 1991; 419: 603–9PubMedCrossRef

51.

Hebert T, Drapeau P, Pradier L, et al. Block of the rate brain IIA sodium channel subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994; 45: 1055–60PubMed

52.

Stefani A, Spadoni F, Bernardi G. Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 1997; 147: 115–22PubMedCrossRef

53.

Song JH, Huang CS, Nagata K, et al. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther 1997; 282: 707–14PubMed

54.

Zona C, Siniscalchi A, Mercuri NB, et al. Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neurosci 1998; 85: 931–8CrossRef

55.

Urbani A, Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 2000; 12: 3567–74PubMedCrossRef

56.

Huang CS, Song JH, Nagata K, et al. Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997; 282: 1280–90PubMed

57.

Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release form rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004; 125: 191–201PubMedCrossRef

58.

Doble A, Hubert JP, Blanchard JC. Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells. Neurosci Lett 1992; 140: 251–4PubMedCrossRef

59.

Hubert JP, Delumeau JC, Glowinski J, et al. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994; 113: 261–7PubMedCrossRef

60.

Huang CS, Song JH, Nagata K, et al. G-proteins are involved in riluzole inhibition of high voltage-activated calcium chanels in rat dorsal root gangion neurons. Brain Res 1997; 762: 235–9PubMedCrossRef

61.

Duprat F, Lesage F, Patel AJ, et al. The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol Pharmacol 2000; 57: 906–12PubMed

62.

Xu L, Enyeart JA, Enyeart JJ. Neuroprotective agent riluzole dramatically slows inactivation of Kvl.4 potassium channels by a voltage-dependent oxidative mechanism. J Pharmacol Exp Ther 2001; 299: 227–37PubMed

63.

Ahn HS, Kim SE, Jang HJ, et al. Interaction of riluzole with the closed inactivated state of Kv4.3 channels. J Pharmacol Exp Ther 2006; 319: 323–31PubMedCrossRef

64.

Debono MW, Le Guern J, Canton T, et al. Inhibition by riluzole of electrophysiological responses mediated by rat kainite and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993; 235: 283–9PubMedCrossRef

65.

Zona C, Cavalcanti S, De Sarro G, et al. Kainate-induced currents in rat cortical neurons in culture are modulated by riluzole. Synapse 2002; 43: 244–51PubMedCrossRef

66.

Albo F, Pieri M, Zona C. Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J Neurosci Res 2004; 78: 200–7PubMedCrossRef

67.

Mizuta I, Ohta M, Ohta K, et al. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 2001; 310: 117–20PubMedCrossRef

68.

Katho-Semba R, Asano T, Ueda H, et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J 2002; 16: 1328–30

69.

Azbill RD, Mu X, Springer JE. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res 2000; 871: 175–80PubMedCrossRef

70.

Dunlop J, Beal Mcllvain H, She Y, et al. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic Superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 2003; 23: 168–96

71.

Frizzo ME, Dall’Onder LP, Dalcin KB, et al. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 2004; 24: 123–8PubMedCrossRef

72.

Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 2003; 23: 2899–910PubMed

73.

Chowdhury GMI, Banasr M, Sanacora G, et al. Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus. J Cereb Blood Flow Metab. In press

74.

Mohammadi B, Lang N, Dengler R, et al. Interaction of high concentrations of riluzole with skeletal muscle sodium channels and adult-type nicotinic receptor channels. Muscle Nerve 2002; 26: 539–45PubMedCrossRef

75.

He Y, Benz A, Fu T, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA-A receptor function. Neuro-pharmacol 2002; 42: 199–209

76.

Coderre TJ, Kumar N, Lefebvre CD, et al. A comparison of the glutamate relecase inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem 2007; 100: 1289–99PubMedCrossRef

77.

Ahn HS, Choi JS, Choi BH, et al. Inhibition of the cloned delayed rectifier K+ channels, Kv1.5 and Kv3.1, by riluzole. Neuroscience 2005; 133: 1007–19PubMedCrossRef

78.

Dietrich D, Kral T, Clusmann H, et al. Presynaptic group II metabotropic glutamate receptors reduce stimulated and spontaneous transmitter release in human dentate gyrus. Neuropharm 2002; 42: 297–305CrossRef

79.

Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharm 2008; 33: 18–41CrossRef

80.

Lipton SA. NMDA receptors, glial cells, and clinical medicine. Neuron 2006; 50: 9–11PubMedCrossRef

81.

Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996; 47: S233–41PubMedCrossRef

82.

Balazs R, Hack N, Jorgensen OS. Stimulation of the N-methyl-D-aspartate receptor has a trophic effect on differentiating cerebellar granule cells. Neurosci Lett 1988; 87: 80–6PubMedCrossRef

83.

Bambrick LL, Yarowsky PJ, Krueger BK. Glutamate as a hippocampal neuron survival factor: an inherited defect in the trisomy 16 mouse. Proc Natl Acad Sci U S A 1995; 92: 9692–6PubMedCrossRef

84.

Ikonomidou C, Bosch F, Miksa M, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999; 283: 70–4PubMedCrossRef

85.

Monti B, Contestabile A. Blockade of the NMDA receptor increases developmental apoptotic elimination of granule neurons and activates caspases in the rat cerebelm. Eur J Neurosci 2000; 12: 3117–23PubMedCrossRef

86.

Balazs R. Trophic effect of glutamate. Curr Top Med Chem 2006; 6: 961–8PubMedCrossRef

87.

Cole AJ, Saffen DW, Baraban JM, et al. Rapid increase of an immediate early gene messenger RNA in hippocampal neurons by synaptic NMDA receptor activation. Nature 1989; 340: 474–6PubMedCrossRef

88.

Carlezon Jr WA, Duman RS, Nestler EJ. The many faces of CREB. TINS 2005; 28: 436–45PubMed

89.

Meberg PJ, Kinney WR, Valcourt EG, et al. Gene expression of the transcription factor NF-kappa B in hippocampus: regulation by synaptic activity. Brain Res Mol Brain Res 1996; 38: 179–90PubMedCrossRef

90.

Marini AM, Jiamg X, Wu X, et al. Role of brain-derived neurotrophic factor and NF-kappaB in neuronal plasticity and survival: from genes to phenotype. Restor Neurol Neurosci 2004; 22: 121–30PubMed

91.

Walton MR, Dragunow M. Is CREB a key to neuronal survival? Trends Neurosci 2000; 23: 48–53PubMedCrossRef

92.

Mattson MP, Culmsee C, Yu Z, et al. Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem 2000; 74: 443–56PubMedCrossRef

93.

Tao X, Finkbeiner DB, Arnold AJ, et al. Ca2+ influx regulates BDNF transcription by CREB family transcription factor dependent mechanism. Neuron 1998; 20: 709–26PubMedCrossRef

94.

Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layer of the retina. Arch Ophthamol 1957; 58: 193–201CrossRef

95.

Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor. Trends Neurosci 1987; 10: 299–302CrossRef

96.

Arundine M, Tymainski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003; 34: 325–37PubMedCrossRef

97.

Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999; 79: 1431–568PubMed

98.

Cluskey S, Ramsden DB. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol Path 2001; 54: 386–92

99.

Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int 2004; 45: 583–95PubMedCrossRef

100.

Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000; 48: 755–65PubMedCrossRef

101.

McShane R, Aerosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2): CD003154

102.

Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synapic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002; 5: 405–15PubMed

103.

Hardingham GE, Bading H. The Yin and Yang of NMDA receptor signaling. Trends Neurosci 2003; 26: 81–9PubMedCrossRef

104.

Hardingham GE. Pro-survival signaling from the NMDA receptor. Biochem Soc Trans 2006; 34: 936–8PubMedCrossRef

105.

Zhang SJ, Steijaert MN, Lau D, et al. Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron 2007; 53: 549–62PubMedCrossRef

106.

Clements JD, Lester RA, Tong G, et al. The time course of glutamate in the synaptic cleft. Science 1992; 258: 1498–501PubMedCrossRef

107.

Herman MA, Jahr CE. Extracellular glutamate concentration in hippocampal slice. J Neurosci 2007; 27: 9736–41PubMedCrossRef

108.

O’Shea RD. Roles and regulation of glutamate transporters in the central nervous system. Clin Exper Pharm Physiol 2002; 29: 1018–23CrossRef

109.

Bergles DE, Jahr CE. Glial contribution to glutamate uptake at Schaffer collateral-commissural synapses in the hippocampus. J Neurosci 1998; 18: 7709–16PubMed

110.

Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996; 16: 675–86PubMedCrossRef

111.

Tanaka K, Watase K, Manabe T, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997; 276: 1699–702PubMedCrossRef

112.

Oliet SHR, Piet R, Poulain DA. Control of glutamate clearance and synaptic efficacy by glial coverage of neurons. Science 2001; 292: 923–6PubMedCrossRef

113.

Piet R, Vargova L, Sykova E, et al. Physiological contribution of the astrocytic environment of neurons to intersynaptic crosstalk. Proc Natl Acad Sci U S A 2004; 101: 2151–5PubMedCrossRef

114.

Jabaudon D, Scanziani M, Gahwiler BH, et al. Acute decrease in net glutamate uptake during energy deprivation. Proc Natl Acad Sci U S A 2000; 97: 5610–5PubMedCrossRef

115.

Jabaudon D, Shimamoto K, Yasuda-Kamatani Y, et al. Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A 1999; 96: 8733–8PubMedCrossRef

116.

Perego C, Vanoni C, Bosi M, et al. The GLT-1 and GLAST glutamate transporters are expressed on morphologically distinct astrocytes and regulated by neuronal activity in primary hippocampal cocultures. J Neurochem 2000; 75: 1076–84PubMedCrossRef

117.

Genoud C, Quairiaux C, Steiner P, et al. Plasticity of astrocytic coverage and glutamate transporter expression in adult mouse cortex. PloS Biology 2006; 4: e343PubMedCrossRef

118.

Tian GL, Lai LC, Guo H, et al. Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem 2007; 282: 1727–37PubMedCrossRef

119.

Lin CI, Orlov I, Ruggiero AM, et al. Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3-18. Nature 2001; 410: 84–8PubMedCrossRef

120.

Jackson M, Song W, Liu MY, et al. Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature 2001; 410: 89–93PubMedCrossRef

121.

Marie H, Billups D, Bedford FK, et al. The amino terminus of the glial glutamate transporter GLT-1 interacts with the LIM protein Ajuba. Mol Cell Neurosci 2002; 19: 152–64PubMedCrossRef

122.

Beart PM, O’Shea RD. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol 2007; 150: 5–17PubMedCrossRef

123.

Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005; 433: 73–7PubMedCrossRef

124.

Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57B1/6J mice. Biol Psychiatry 2007; 61: 250–2PubMedCrossRef

125.

Moran MM, McFarland K, Melendez RI, et al. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynpatic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005; 25: 6389–93PubMedCrossRef

126.

Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006; 209: 2304–11PubMedCrossRef

127.

Mathew SJ, Price RB, Mao X, et al. Hippocampal N-acetylasparate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry 2008; 63: 891–8PubMedCrossRef

128.

Groeeveld GJ, van Kan HJM, Sastre Toraño J, et al. Inter- and intra-individual variability of riluzole serum concentrations in patients with ALS. J Neurol Sci 2001; 191: 121–5CrossRef

129.

Mohammadi B, Krampfl K, Moschref H, et al. Interaction of the neuroprotective drug riluzole with GABA(A) and glycine receptor channels. Eur J Pharmacol 2001; 415: 135–40PubMedCrossRef

130.

Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and TrkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neuosci 1995; 15: 7539–47

131.

Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116–27PubMedCrossRef

132.

Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104–10PubMed

133.

Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006; 16: 239–49PubMedCrossRef

134.

Svenningsson P, Tzavara ET, Witkin JM, et al. Involvement of striatal and extrastriatal DARP-32 in biochemical effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A 2002; 99: 3182–7PubMedCrossRef

135.

Witkin JM, Marek GJ, Johnson BG, et al. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 2007; 6: 87–100PubMedCrossRef

136.

Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharm 2007; 32: 793–802CrossRef

137.

Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluozle in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249: 609–15PubMedCrossRef

138.

Yanagisawa N, Tashiro K, Tohgi H, et al. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi 1997; 182: 851–66

139.

Riviere M, Meininger V, Zeisser P, et al. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55: 526–8PubMedCrossRef

140.

Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987; 22: 575–9PubMedCrossRef

141.

Rothstein JD, Martin LJ, Kunci RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326: 1464–8PubMedCrossRef

142.

Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999; 81: 163–221PubMedCrossRef

143.

LeWitt PA. Clinical trials of neuroprotection for Parkinson’s disease. Neurology 2004; 63(S2): S23–31PubMedCrossRef

144.

Jancovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson’s disease. Parkinsonism Relat Disord 2002; 8: 271–6CrossRef

145.

Braz CA, Borges V, Ferraz HB. Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 2004; 27: 25–9PubMedCrossRef

146.

Bara-Jimenez W, Dimitrova TD, Sherzai A, et al. Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov Disord 2006; 21: 1380–3PubMedCrossRef

147.

Seppi K, Peralta C, Diem-Zangerl A, et al. Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurosci 2006; 13: 1146–8

148.

Seppi K, Mueller J, Bodner T, et al. Riluzole in Hntington’s disease (HD): an open-label study with one year follow up. J Neurol 2001; 248: 866–9PubMedCrossRef

149.

Huntington Study Group. Dosage effects of riluzole in Huntington’s disease: a multicenter placebo-controlled study. Neurology 2003; 61: 1551–6CrossRef

150.

Galer BS, Twilling LL, Harle J, et al. Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions. Neurology 2000; 55: 971–5PubMedCrossRef

151.

Romettino S, Lazdunski M, Gottesmann C. Anticonvulsant and sleep-waking influences of riluzole in a rat model of absence epilepsy. Eur J Pharmacol 1991; 199: 371–3PubMedCrossRef

152.

De Sarro G, Siniscalchi A, Ferreri G, et al. NMDA and AMP A/ kainite receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice. Eur J Pharmacol 2000; 408: 25–34PubMedCrossRef

153.

Borowicz KK, Sekowski A, Drelewska E, et al. Riluzole enhances the anti-seizure action of conventional antiepileptic drugs against pentetrazole-induced convulsions in mice. Pol J Pharmacol 2004; 56: 187–93PubMed

154.

Kim JE, Kim DS, Kwak SE, et al. Anti-glutamatergic effect of riluzole: comparison with valproic acid. Neuroscience 2007; 147: 136–45PubMedCrossRef

155.

Kugaya A, Sanacora G. Beyond momoamines: glutamatergic function in mood disorders. CNS Spectr 2005; 10: 808–19PubMed

156.

Pittenger C, Sanacora G, Krystal J. The NMDA receptor as a therapeutic target in major depression. CNS Neurol Disord Drug Targets 2007; 6: 101–15PubMedCrossRef

157.

Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 2006; 147: 1–25PubMedCrossRef

158.

Hasler G, van der Veen JW, Tumonis T, et al. Reduced prefrontal glutamate/glutamine and γ-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007; 64: 193–200PubMedCrossRef

159.

Bhagwagar Z, Wylezinska M, Jezzard P, et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 2007; 61: 806–12PubMedCrossRef

160.

Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998; 95: 13290–5PubMedCrossRef

161.

Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 1085–98PubMedCrossRef

162.

Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007; 6: 219–33PubMedCrossRef

163.

Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001; 55: 585–95PubMedCrossRef

164.

Cotter DR, Mackay D, Chana G, et al. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002; 12: 386–94PubMedCrossRef

165.

Banasr M, Valentine GW, Li XY. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol Psychiatry 2007; 62: 496–504PubMedCrossRef

166.

Bansar M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry. In press

167.

Zarate Jr CA, Quiroz J, Payne J, et al. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Translational Neurosci 2002; 36: 35–83

168.

Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics in major depression. Biol Psychiatry 2003; 53: 707–42PubMedCrossRef

169.

Banasr M, Chowdhury GMI, Terwilleger R, et al. Stress-induced glial pathology and depressive behaviors are prevented by riluzole. Mol Psychiatry. In press

170.

Montgomery SA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9PubMedCrossRef

171.

Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5PubMedCrossRef

172.

Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997; 36: 844–52PubMedCrossRef

173.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62PubMedCrossRef

174.

Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1106–11

175.

Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–35.PubMedCrossRef

176.

Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856–64PubMedCrossRef

177.

Thase ME, Bhargava M, Sach GS. Treatment of bipolar depression: current status, continued challenges, and the STEP-BD approach. Psychiatr Clin North Am 2003; 26: 495–518PubMedCrossRef

178.

Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003; 5: 407–20PubMedCrossRef

179.

Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropharmacol Biol Psychiatry 2006; 30: 969–95CrossRef

180.

Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. Int J Neuropsychopharm 2001; 4: 179–90CrossRef

181.

Pittenger C, Naungayan C, Kendell SF, et al. Visual hallucinations from the addition of riluzole to memantine and bupropion. J Clin Psychopharmacol 2006; 26: 218–20PubMedCrossRef

182.

Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharm 2005; 30: 1735–40CrossRef

183.

Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 769–76PubMedCrossRef

184.

Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 778–85PubMedCrossRef

185.

Stewart SE, Fagerness JA, Platko J, et al. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsych Genet 2007; 144: 1028–33

186.

Mataix-Cols D, Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005; 162: 228–38PubMedCrossRef

187.

Samuels J, Shugart YY, Grados MA, et al. Significant linkage to compulsive hoarding on chromosome 14 in families with obsessive-compulsive disorder: results from the OCD Collaborative Genetics Study. Am J Psychiatry 2007; 164: 493–9PubMedCrossRef

188.

Saxena S. Is compulsive hoarding a genetically and neurobiologically discrete syndrome? Implications for diagnostic classification. Am J Psychiatry 2007; 164: 380–4PubMedCrossRef

189.

Sasso DA, Kalanithi PS, Trueblood KV, et al. Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors. J Clin Psychopharmacol 2006; 26: 685–7PubMedCrossRef

190.

Hollander E. Obsessive compulsive related disorders. Washington, DC: American Psychiatric Press, 1993

191.

Gunstad J, Phillips KA. Axis I comorbidity in body dysmorphic disorder. Compr Psychiatry 2003; 44: 270–6PubMedCrossRef

192.

Lieb K, Zanarini MC, Schmahl C, et al. Borderline personality disorder. Lancet 2004; 364: 453–61PubMedCrossRef

193.

Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychiatry 2005; 66: 1492–3PubMedCrossRef

194.

Bloch MH, Landeros-Weisenberger A, Dombrowski P, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry 2007; 62: 839–46PubMedCrossRef

195.

Coric V, Kelmendi B, Pittenger C, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania. J Clin Psychiatry 2007; 68: 170–1PubMedCrossRef

196.

O’Sullivan RL, Keuthen NJ, Hayday CF. The Massachusetts General Hospital (MGH) hairpulling scale: 2. Reliability and validity. Psychother Psychosom 1995; 64: 146–48PubMedCrossRef

197.

Bensimon G, Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin Drug Saf 2004; 3: 525–34PubMedCrossRef

198.

Lacomblez L, Dibm M, Doppler V, et al. Tolerance of riluzole in a phase IIIb clinical trial. Therapie 2002; 57: 65–71PubMed

199.

Castells LI, Gamez J, Cervera C, et al. Icteric toxic hepatitis associated with riluzole [letter]. Lancet 1998; 351: 648PubMedCrossRef

200.

Remy AJ, Acmu W, Ramos J, et al. Acute hepatitis after riluzole administration. J Hepatol 1999; 30: 527–30PubMedCrossRef

201.

Rilutek® package insert. Bridgewater (NJ). sanofi-aventis, 2006

202.

Viallon A, Page Y, Bertrand JC. Methemoglobinemia due to riluzole. N Engl J Med 2000; 343: 665–6PubMedCrossRef

203.

Bodner T, Jenner C, Benke T, et al. Intoxication with rilzole in Huntington’s disease. Neurology 2001; 57: 1141–3PubMedCrossRef

204.

Haaxma CA, Kremer HP, van de Warrenburg BP. Delayed amnesic syndrome after riluzole autointoxication in Huntington disease. Neurology 2006; 66: 1123–4PubMedCrossRef

Titel: Riluzole in the Treatment of Mood and Anxiety Disorders
verfasst von: Dr Christopher Pittenger
Vladimir Coric
Mounira Banasr
Michael Bloch
John H. Krystal
Gerard Sanacora
Publikationsdatum: 01.09.2008
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 9/2008
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200822090-00004

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2008

CNS Adverse Events Associated with Antiepileptic Drugs

Spotlight on Olanzapine/Fluoxetine in Acute Bipolar Depression

Interferon-β-1b

Role of the Glutamatergic System in Nicotine Dependence